| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04742348 Details | 2023-02-13 Interventional | 4 | 0 | Carbidopa Carbidopa, levo… Levodopa Alcohol Drinkin… | COVID-19 and expiration of funding - | |||
| NCT03546556 Details | 2023-02-13 Interventional | 1 | 10 | Alovudine Dideoxynucleosi… Graft vs Host D… Graft Vs Host D… | Study terminated due to COVID-19 pandemic and not being able to perform PET/MR scans on
participants. - | |||
| NCT03762317 Details | 2023-02-10 Interventional | 4 | 10 | Clonidine Neonatal Abstin… Syndrome | Study was initially suspended due to IND application and later terminated due to the difficulty
of obtaining consent during COVID period - | |||
| NCT03042546 Details | 2023-02-10 Interventional | 4 | 1 | Calcium Fractures, Bone Tibial Fracture… Open tíbia Fra… | Study halted prematurely and will not resume; participants are no longer being examined or
receiving intervention. Low enrollment and PI leaving institution - | |||
| NCT04754334 Details | 2023-02-09 Interventional | 3 | 346 | Insulin Diabetes Mellit… Diabetes Mellit… T2DM (Type 2 Di… | The ORA-D-013-2 protocol was terminated based on the primary results analyzed at week 26 in the
ORA-D-013-1 protocol. - | |||
| NCT04606576 Details | 2023-02-09 Interventional | 3 | 710 | Insulin Insulin, Globin… Diabetes Mellit… Diabetes Mellit… Type 2 Diabetes… | ORA-D-013-1 was terminated based on the primary results analyzed at the end of the treatment,
week 26. - | |||
| NCT04154787 Details | 2023-02-09 Interventional | 2 | 37 | Rituximab Glomerulonephri… Glomerulonephri… Kidney Diseases | Sponsor decision - | |||
| NCT03844633 Details | 2023-02-09 Interventional | 4 | 49 | Medroxyprogeste… Medroxyprogeste… Delay in Time t… | Because of insufficient enrollment, we closed the RCT and replaced it with an observational
design - | |||
| NCT02624479 Details | 2023-02-09 Interventional | 1 | 0 | Sodium thiosulf… Healthy | Formulations could never be successfully produced - | |||
| NCT00568672 2007-000512-82 Details | 2023-02-09 Interventional | 3 | 0 | Olanzapine Depression Depressive Diso… Depressive Diso… Relapse Rate of… Safety of Olanz… | Withdrawn because of personal ressources before inclusion of the first patient - | |||
| NCT05279235 Details | 2023-02-08 Interventional | 3 | 290 | Favipiravir COVID-19 Moderate to Sev… | Development strategy adjustment - | |||
| NCT05156632 Details | 2023-02-08 Interventional | 3 | 0 | Aluminum Hydrox… Vaccines COVID-19 | The plan has changed - | |||
| NCT04718961 2020-003448-96 Details | 2023-02-08 Interventional | 2 | 4 | Volixibat Cholestasis Cholestasis, In… Pregnancy Compl… Intrahepatic Ch… | Due to company's assessment of enrollment feasibility. - | |||
| NCT04290871 Details | 2023-02-08 Interventional | 2 | [1 Refs] | 0 | Nitric Oxide COVID-19 Severe Acute Re… Syndrome Coronavirus Cov… SARS (Severe Ac… | The study will start to enroll patients soon - | ||
| NCT04095858 NCT04976699 Details | 2023-02-08 Interventional | 3 | 11 | Methotrexate Tacrolimus Graft vs Host D… Leukemia Myelodysplastic… Precursor Cell … Acute Graft Ver… Acute Lymphobla… Acute Myeloid L… Hematopoietic S… | Business Reasons - | |||
| NCT03941496 Details | 2023-02-08 Interventional | 1/2 | 0 | Azacitidine Tuberculosis Tuberculosis, P… | The study was halted prematurely due to Bristol-Myers Squibb's (BMS) decision to withdraw
support for this study. - | |||
| NCT03599518 Details | 2023-02-08 Interventional | 1 | 20 | Gefitinib Carcinoma, Non-… Lung Neoplasms Non Small Cell … | This study was terminated based on a business decision by the Sponsor. The sponsor decided to terminate the study at the end of the Dose Escalation part and the Dose Expansion part was not conducted. | |||
| NCT03504410 Details | 2023-02-08 Interventional | 3 | 200 | Cytarabine Etoposide Fludarabine Mitoxantrone Relapsed/Refrac… | Futile - | |||
| NCT03236649 Details | 2023-02-08 Interventional | 3 | 89 | Sorafenib Carcinoma Carcinoma, Hepa… Hepatocellular … | Because the clinical development plan has been changed. - | |||
| NCT05363436 Details | 2023-02-06 Interventional | 4 | 159 | Oxycodone Opioid-Related … Opioid Abuse Opioid Misuse Pain | Recruitment Reorganzing - |